Form 4: Dyne Therapeutics Director Sells Shares
Insider Transaction Report
Dyne Therapeutics Director Jason P. Rhodes reported the sale of common stock valued at approximately $21.28 per share on June 26, 2026, and $21.14 per share on June 29, 2026, pursuant to a Rule 10b5-1 trading plan.
Summary
- Director Jason P. Rhodes of Dyne Therapeutics, Inc. reported transactions involving the sale of common stock.
- These sales occurred on June 26, 2026, and June 29, 2026.
- The sales were executed under a Rule 10b5-1 trading plan adopted on March 19, 2026.
- On June 26, 2026, sales were made at a weighted average price of $21.28 per share, with individual transactions ranging from $21.00 to $21.61.
- On June 29, 2026, sales were made at a weighted average price of $21.14 per share, with individual transactions ranging from $21.00 to $21.3247.
- The reporting person disclaims beneficial ownership of certain shares held indirectly through various Atlas Venture funds, except to the extent of his pecuniary interest.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as the sales were conducted under a pre-arranged trading plan, indicating a planned divestment rather than a reaction to negative company news.
Negatives
- Director Jason P. Rhodes sold a significant number of shares, totaling over 300,000 shares across the reported transactions.
Future Outlook
The filing does not contain forward-looking statements or guidance.
Industry Context
StockSavvy.ai notes that insider sales, especially under a Rule 10b5-1 plan, are common for executives and directors to diversify holdings or manage personal finances. The specific timing and volume of these sales can be monitored for insights into management's perception of the company's valuation.
Stakeholder Impact
- Shareholders may view the sale of a significant number of shares by a director with caution, although the Rule 10b5-1 plan mitigates concerns about insider trading based on non-public information.
Key Dates
| Date | Description |
|---|---|
| 03/19/2026 | Date Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 06/26/2026 | Earliest transaction date reported for stock sales. |
| 06/29/2026 | Second transaction date reported for stock sales. |
| 06/30/2026 | Date the Form 4 was signed by the attorney-in-fact. |
Keywords
Dyne Therapeutics, DYN, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Director Transaction, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.